Development status: Experimental

Gram-positive activity

Mechanism of Action/Target pathogen: Active against vancomycin-resistant <i>Enterococcus</i> sp.; dissipates membrane potential

Additional information: Synthetic compound; approved by FDA as a thrombopoietin receptor agonist; a repurposed drug; shows synergistic effect with aminoglycosides; no haemolytic activity observed; shows human cell line toxicity at 10xMIC; reduces bacterial load with tobramycin in murine peritonitis infection model with vancomycin-resistant <i>Enterococcus</i>